metronidazole has been researched along with Cockayne Syndrome in 2 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Cockayne Syndrome: A syndrome characterized by multiple system abnormalities including DWARFISM; PHOTOSENSITIVITY DISORDERS; PREMATURE AGING; and HEARING LOSS. It is caused by mutations of a number of autosomal recessive genes encoding proteins that involve transcriptional-coupled DNA REPAIR processes. Cockayne syndrome is classified by the severity and age of onset. Type I (classical; CSA) is early childhood onset in the second year of life; type II (congenital; CSB) is early onset at birth with severe symptoms; type III (xeroderma pigmentosum; XP) is late childhood onset with mild symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Through the Cockayne Syndrome Natural History Study, we have identified 8 cases of acute hepatic failure after metronidazole administration (8% of our cohort), 3 of which were fatal." | 7.81 | Metronidazole Toxicity in Cockayne Syndrome: A Case Series. ( Munkley, J; O'Kelly, S; Stark, Z; Strong, A; Wilson, BT, 2015) |
| " Through the Cockayne Syndrome Natural History Study, we have identified 8 cases of acute hepatic failure after metronidazole administration (8% of our cohort), 3 of which were fatal." | 3.81 | Metronidazole Toxicity in Cockayne Syndrome: A Case Series. ( Munkley, J; O'Kelly, S; Stark, Z; Strong, A; Wilson, BT, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hunaut, T | 1 |
| Boulagnon-Rombi, C | 1 |
| Thorn, H | 1 |
| Doco-Fenzy, M | 1 |
| Thiéfin, G | 1 |
| Wilson, BT | 1 |
| Strong, A | 1 |
| O'Kelly, S | 1 |
| Munkley, J | 1 |
| Stark, Z | 1 |
1 review available for metronidazole and Cockayne Syndrome
| Article | Year |
|---|---|
Hepatotoxicity of metronidazole in Cockayne syndrome: A clinical report.
Topics: Adult; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Cockayne Syndrome; Humans; Jau | 2022 |
1 other study available for metronidazole and Cockayne Syndrome
| Article | Year |
|---|---|
Metronidazole Toxicity in Cockayne Syndrome: A Case Series.
Topics: Adolescent; Anti-Infective Agents; Cockayne Syndrome; Fatal Outcome; Female; Gastrointestinal Diseas | 2015 |